Conduit Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Conduit Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
SAN DIEGO and LONDON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit" or the "Company"), today announced it will be participating in the H.C. Wainwright 26th Annual Global Investment Conference, being held September 9-11, 2024. Dr. David Tapolczay, Founder and CEO of Conduit, will give a virtual presentation available on-demand starting on September 9th at 7:00 am ET/12:00 pm BST. Dr. Tapolczay will also be available for in-person, one-on-one investor meetings throughout the conference being held at Lotte New York Palace Hotel, 455 Madison Avenue, New York City.
2024年8月28日,SAN DIEGO和LONDON(全球華氏通訊社) - Conduit Pharmaceuticals Inc.(Nasdaq: CDT)(以下簡稱「Conduit」或「公司」)宣佈將參加2024年9月9日至11日舉辦的H.C.Wainwright第26屆全球投資大會。Conduit創始人兼首席執行官David Tapolczay博士將於9月9日上午7:00(東部標準時間)/下午12:00(英國夏令時)開始提供可隨時點播的虛擬演示。Tapolczay博士還將在會議期間在紐約市Madison Avenue 455號Lotte New York Palace Hotel舉行的面對面投資者會議上提供一對一會議。
To view Dr. Tapolczay's presentation, please use the following link to register via H.C. Wainwright's website (). A webcast of the presentation will also be available on the Company Events section of the Company's website at ().
要查看Tapolczay博士的演示,請使用以下鏈接通過H.C. Wainwright的網站進行註冊()。演示的網絡直播也可以在公司網站的公司活動部分上找到()。
About Conduit Pharmaceuticals
關於Conduit Pharmaceuticals
Conduit is a multi-asset, clinical stage, disease-agnostic life science company delivering an efficient model for compound development. Conduit both acquires and funds the development of Phase 2-ready assets and then seeks an exit through third-party license deals following successful clinical trials. Led by a highly experienced team of pharmaceutical executives including Dr. David Tapolczay and Dr. Freda Lewis-Hall, this novel approach is a departure from the traditional pharma/biotech business model of taking assets through regulatory approval.
Conduit是一家多資產、臨床階段、無病症限制型生命科學公司,提供高效的化合物開發模型。Conduit同時獲得並資助開發已準備好進行2期試驗的資產,然後在成功進行臨床試驗後,尋求第三方許可協議出口。這種創新方法由製藥行業高管團隊領導,包括大衛·塔波爾卡齊博士和弗裏達·路易斯-霍爾博士,是傳統制藥/生物科技業務模式的一個變革。
Forward-Looking Statements
前瞻性聲明
This press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding Conduit's future results of operations and financial position, Conduit's business strategy, prospective product candidates, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated studies and business endeavors with third parties, and future results of current and anticipated product candidates, are forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to; the inability to maintain the listing of Conduit's securities on Nasdaq; the ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected by, among other things, competition; the ability of the combined company to grow and manage growth economically and hire and retain key employees; the risks that Conduit's product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities on a timely basis or at all; changes in applicable laws or regulations; the possibility that Conduit may be adversely affected by other economic, business, and/or competitive factors; and other risks as identified in filings made by Conduit with the U.S. Securities and Exchange Commission. Moreover, Conduit operates in a very competitive and rapidly changing environment. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond Conduit's control, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, Conduit assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Conduit gives no assurance that it will achieve its expectations.
本新聞稿包含某些根據聯邦證券法義務的前瞻性聲明。本新聞稿中除歷史事實以外的所有陳述,包括關於Conduit未來業績和財務狀況、Conduit業務策略、預期產品候選者、產品批准、研發成本、時間和成功的可能性、管理層在未來運營方面的計劃和目標、當前和預期研究以及與第三方的商業活動的預期結果以及當前和預期產品候選者的預期結果等均爲前瞻性聲明。這些前瞻性聲明通常以「相信」、「預期」、「估計」、「意味着」、「策略」、「未來」、「機會」、「計劃」、「可能」、「應該」、「將」、「將會」、「將繼續」、「可能導致」的類似表達方式爲特徵。這些前瞻性聲明面臨許多風險、不確定因素和假設,其中一些風險和不確定因素無法預測或量化,另一些風險和不確定因素超出了Conduit的控制範圍。由於前瞻性聲明天然上面臨風險和不確定因素,其中一些無法預測或量化,而另一些因素超出了Conduit的控制,因此您不應將這些前瞻性聲明作爲未來事件的預測。因爲前瞻性聲明天然上面臨風險和不確定因素,其中一些無法預測或量化,而另一些因素超出了Conduit的控制,因此您不應將這些前瞻性聲明作爲未來事件的預測。
Investors
Bill Begien
Conduit Pharmaceuticals Inc.
bb@conduitpharma.com
投資者
Bill Begien
Conduit Pharmaceuticals Inc.
bb@conduitpharma.com